The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California.

Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference.

1- A new analysis shows Provenge may have a median survival advantage of as much as 7.8 months–the largest ever for any late stage cancer treatment.

2- A study in men who got Provenge before their prostates were removed showed that a they developed a significant immune system attack on their tumors when their prostates were examined after removal.

3- Another study showed that the biggest immune boost was in men in the earlier stage of disease — This indicates that it is important to get Provenge as early as possible.

Here are the links to the abstracts:




All three posters are great news for men with advanced prostate cancer, a longer survival advantage and positive benefit with earlier use of Provenge.

Joel T Nowak, M.A., M.S.W.